DaVita Inc. - DVA STOCK NEWS

On February 14, 2022, DaVita announced it will provide four consecutive weeks of paid leave for employees who donate their bone marrow, liver, or kidney. This initiative aims to alleviate concerns about lost wages during the recovery period after donation, which typically follows a 4-6 day hospital stay. Over 106,000 individuals are currently awaiting organ transplants in the U.S., while approximately 6,500 living donor transplants were conducted in 2021. DaVita's recent investments in transplant innovations, including the acquisition of MedSleuth, reflect its commitment to improving organ donation accessibility.

DaVita reported strong financial results for 2021, with diluted earnings per share rising to $8.90, up 39.3% year-over-year. The company achieved consolidated revenues of $11.619 billion for the year, a growth driven by favorable government rates and an improved commercial mix. Operating income reached $1.797 billion, with fourth-quarter earnings also showing a significant increase. Despite the challenges posed by COVID-19, DaVita's dedication to patient care remained strong, leading to effective financial performance.

DaVita Inc. (NYSE: DVA) announced its quarterly conference call to discuss fourth quarter results scheduled for February 10, 2022, at 5:00 p.m. Eastern Time. Results will be released after market close on the same day. The call will be webcast and accessible via DaVita's investor relations website. DaVita, a leading kidney care provider, serves 203,000 patients at 2,822 outpatient dialysis centers in the U.S. and operates in ten countries worldwide. The company focuses on improving healthcare delivery and clinical quality.

On January 19, 2022, DaVita Integrated Kidney Care launched 11 value-based care programs aimed at supporting approximately 25,000 kidney patients across the U.S. These initiatives align with the government's new Kidney Care Choices (KCC) model, which commenced on January 1, 2022, and spans five years. The program encourages proactive management of chronic kidney disease (CKD) to reduce the need for emergency dialysis, ultimately improving patient outcomes and reducing costs. DaVita IKC aims to double patient participation in integrated kidney care within the first performance year.

On January 18, 2022, DaVita announced its acquisition of MedSleuth, a software company focused on improving kidney and liver transplantation processes. This acquisition enhances DaVita's commitment to innovation in transplant care, aiming to streamline access and improve patient outcomes. MedSleuth’s BREEZE™ software aids in candidate evaluation and increases living donation rates, while MATCHGRID™ improves donor-recipient matching. With this purchase, DaVita aims to break down barriers in kidney care, enhancing health equity and patient experiences in transplantation.

DaVita celebrated its teammates for their outstanding contributions in 2021, notably improving care for kidney patients. CEO Javier Rodriguez highlighted the team's resilience amid challenges, focusing on enhancing kidney care services. Key achievements include administering approximately 217,000 COVID-19 vaccines, achieving high international vaccination rates, and providing at-home dialysis for over 30,000 patients. Additionally, more than 7,500 patients received kidney transplants, reflecting a 3% increase from the previous year. The company is committed to innovation and expanding its integrated care model to further serve communities worldwide.

DaVita Integrated Kidney Care (IKC) has appointed Dr. David Roer as its new chief medical officer, leading a team of experienced nephrologists to enhance care delivery. The team aims to improve patient care for chronic kidney disease and increase access to home dialysis and kidney transplantation. DaVita IKC currently manages over 30,000 patients and anticipates more than doubling its patient population in 2022 due to new Medicare payment models. This initiative aligns with DaVita's goal of advancing health equity in kidney care.

DaVita Inc has achieved a significant milestone by becoming the first kidney care provider to operate entirely on renewable energy for its North American facilities. This initiative, completed in partnership with Longroad Energy, involved constructing a wind farm and a solar farm in Texas. The company now aims for 100% renewable energy globally by 2025 and has already reduced carbon emissions per dialysis treatment by 19%. Other sustainability efforts include installing energy-efficient systems in 1,200 centers and diverting over 6 million pounds of waste from landfills.